# Nuclide record opp-her3-imaging-crossover (opportunity). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/opportunities/opp-her3-imaging-crossover/>
  a schema:CreativeWork ;
  nuclide:kind "opportunity" ;
  schema:identifier "opp-her3-imaging-crossover" ;
  schema:name "HER3 imaging, and why three tracers stalled"@en ;
  schema:alternateName "HER3 PET"@en ;
  schema:description "HER3 sits on most lung cancers and there are drugs aimed at it, so a scan showing which tumours carry it looks obvious. Three attempts were made and all three stopped, largely because the drug's own trials could not show that how much HER3 a tumour has predicts whether the drug works."@en ;
  schema:url <https://nuclide.cc/opportunities/opp-her3-imaging-crossover/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06222489>, <https://www.nature.com/articles/s41467-024-50056-y>, <https://daiichisankyo.us/press-releases/-/article/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer>, <https://pmc.ncbi.nlm.nih.gov/articles/PMC12758208/>, <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf> ;
  nuclide:tag "target crossover", "worked negative", "lung", "companion diagnostic" ;
  nuclide:related <https://nuclide.cc/isotopes/zr-89/>, <https://nuclide.cc/isotopes/cu-64/> ;
  nuclide:indications <https://nuclide.cc/indications/nsclc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/immuno-pet/>, <https://nuclide.cc/technologies/pet-ct/> ;
  nuclide:targets <https://nuclide.cc/targets/her3/> .